Tigermed staged a spike-and-fade session, touching HK$43.30 in the morning before sliding to HK$39.28 at 14:43 BJ and closing at HK$40.20 on 1.6779 million shares, as broad weakness across CXO names, Genscript Bio foremost among them, weighed on sentiment. That price action sits awkwardly against fundamentals: Q2 2026 revenue rose 19.15% year on year to HK$2.20 billion, yet net profit swung to a HK$533.9 million loss, down 323.62%, with net margin at -24.25%, while Goldman Sachs still expects mainland CRO and CDMO names to sustain growth in Q3 and lifted its average target price by 9%. The close leaves the stock below both its 20-day moving average of HK$44.825 and its 60-day average of HK$41.745, down 5.28% year to date and 29.47% below its February 9 high of HK$57, though the company had bought back 20.9635 million A-shares by end-September.